Updated results with ONO/GS-4059 in patients with CLL. (A) Updated PFS curve for CLL patients. Mean duration on study was 26.6 months and estimated median PFS was 38.5 months. (B) Case example: Recurrent lymphocytosis shown in TP53 mutant CLL patient following an initial lymph nodal response for 31 cycles on 40 mg OD ONO/GS-4059; the patient subsequently responded for a further 12 months to 600 mg OD, with a second lymphocytosis (1.74-fold increase; initial 1.81-fold increase) and lymph nodal response.